MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, Z.-G.
Right arrow Articles by Jacobson, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, Z.-G.
Right arrow Articles by Jacobson, K. A.

Vol. 63, Issue 5, 1021-1031, May 2003

Identification of Essential Residues Involved in the Allosteric Modulation of the Human A3 Adenosine Receptor

Zhan-Guo Gao, Soo-Kyung Kim, Ariel S. Gross, Aishe Chen, Joshua B. Blaustein, and Kenneth A. Jacobson

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland

We examined the effects on allosteric modulation and ligand binding of the mutation of amino acid residues of the human A3 adenosine receptor (A3AR) that are hypothesized to be near one of three loci: the putative sodium binding site, the putative ligand binding site, and the DRY motif in transmembrane helical domain 3. The effects of three heterocyclic allosteric modulators [the imidazoquinoline 2-cyclopentyl-4-phenylamino-1H-imidazo[4,5-c]quinoline (DU124183), the pyridinylisoquinoline 4-methoxy-N-[7-methyl-3-(2-pyridinyl)-1-isoquinolinyl]benzamide (VUF5455), and the amiloride analog 5-(N,N-hexamethylene)-amiloride] on the dissociation of the agonist radioligand, N6- (4-amino-3-[125I]iodobenzyl)-5'-N-methylcarboxamidoadenosine, were compared at wild-type (WT) and mutant A3ARs. The F182A5.43 and N274A7.45 mutations eliminated the allosteric effects of all three modulators but had little effect on agonist binding. The N30A1.50 and D58N2.50 mutations abolished the allosteric effects of DU124183 and VUF5455, but not HMA, whereas the D107N3.49 mutation abolished the effects of DU124183, but not HMA or VUF5455. The T94A3.36, H95A3.37, K152AEL2, W243A6.48, L244A6.49, and S247A6.52 mutations did not influence allosteric effects of the modulators. Sodium ions (100 mM), which modulate agonist binding at a variety of receptors, caused an ~80% inhibition of agonist binding in WT A3ARs but did not show any effect on D58N2.50, D107N3.49, and F182A5.43 mutant receptors. In contrast, NaCl induced a modest increase of agonist binding in N30A1.50 and N274A7.45 mutant receptors. NaCl decreased the dissociation rate of the antagonist radioligand [3H]8-ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2.1-i]purin-5-one (PSB-11) at the WT A3ARs, but not the D58N2.50 mutant receptor. The results were interpreted using a rhodopsin-based molecular model of the A3AR to suggest multiple binding modes of the allosteric modulators.


Copyright © 2003 by U.S. Government



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
B. Holst, T. M. Frimurer, J. Mokrosinski, T. Halkjaer, K. B. Cullberg, C. R. Underwood, and T. W. Schwartz
Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor
Mol. Pharmacol., January 1, 2009; 75(1): 44 - 59.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics